Drug intelligence / Profile preview

Carboplatin + Doxorubicin + Paclitaxel Combination

Development stage
Phase 2
Lead developer
Johnson Matthey
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous
01

Overview

The combination of carboplatin, doxorubicin, and paclitaxel is a chemotherapy regimen used primarily for treating various types of cancer, particularly endometrial cancer. This combination leverages the different mechanisms of action of these three drugs to effectively target cancer cells. ## Mechanism of Action This combination therapy works through multiple mechanisms: - **Carboplatin**: A platinum-based chemotherapy drug that forms cross-links with DNA, interfering with DNA repair mechanisms and causing cell death. - **Doxorubicin**: An anthracycline antibiotic that intercalates with DNA and inhibits topoisomerase II, preventing DNA replication and transcription. - **Paclitaxel**: A taxane that stabilizes microtubules, preventing their breakdown during cell division and leading to cell death. Together, these drugs target cancer cells at different points in their life cycle, potentially increasing efficacy compared to single-agent therapy[1][2].

02

Targets

DNATOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))Microtubule

Beyond the preview

Go deeper on Carboplatin + Doxorubicin + Paclitaxel Combination.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carboplatin + Doxorubicin + Paclitaxel Combination.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call